AbbVie annual revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie Revenue Growth & History (ABBV)
AbbVie reported $61.16B in revenue for fiscal 2025, an increase of 8.57% from the previous fiscal year.
View full AbbVie company overviewAbbVie annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $61.16B | $4.83B | +8.57% |
| 2024 | 2024-12-31 | $56.33B | $2.02B | +3.71% |
| 2023 | 2023-12-31 | $54.32B | −$3.74B | −6.44% |
| 2022 | 2022-12-31 | $58.05B | $1.86B | +3.30% |
| 2021 | 2021-12-31 | $56.20B | $10.39B | +22.69% |
| 2020 | 2020-12-31 | $45.80B | $12.54B | +37.69% |
| 2019 | 2019-12-31 | $33.27B | $513.0M | +1.57% |
| 2018 | 2018-12-31 | $32.75B | $4.54B | +16.08% |
| 2017 | 2017-12-31 | $28.22B | $2.58B | +10.06% |
| 2016 | 2016-12-31 | $25.64B | $2.78B | +12.16% |
| 2015 | 2015-12-31 | $22.86B | $2.90B | +14.52% |
| 2014 | 2014-12-31 | $19.96B | $1.17B | +6.23% |
| 2013 | 2013-12-31 | $18.79B | $410.0M | +2.23% |
| 2012 | 2012-12-31 | $18.38B | $936.0M | +5.37% |
| 2011 | 2011-12-31 | $17.44B | — | — |
AbbVie quarterly revenue
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $16.99B | $1.57B | +10.16% |
| Q1 2026 | 2026-03-31 | $15.00B | $1.66B | +12.43% |
| Q4 2025 | 2025-12-31 | $16.62B | $1.52B | +10.04% |
| Q3 2025 | 2025-09-30 | $15.78B | $1.32B | +9.10% |
| Q2 2025 | 2025-06-30 | $15.42B | $961.0M | +6.65% |
| Q1 2025 | 2025-03-31 | $13.34B | $1.03B | +8.39% |
| Q4 2024 | 2024-12-31 | $15.10B | $801.0M | +5.60% |
| Q3 2024 | 2024-09-30 | $14.46B | $533.0M | +3.83% |
| Q2 2024 | 2024-06-30 | $14.46B | $597.0M | +4.31% |
| Q1 2024 | 2024-03-31 | $12.31B | $85.0M | +0.70% |
| Q4 2023 | 2023-12-31 | $14.30B | −$820.0M | −5.42% |
| Q3 2023 | 2023-09-30 | $13.93B | −$885.0M | −5.97% |
| Q2 2023 | 2023-06-30 | $13.87B | −$718.0M | −4.92% |
| Q1 2023 | 2023-03-31 | $12.22B | −$1.31B | −9.70% |
| Q4 2022 | 2022-12-31 | $15.12B | $235.0M | +1.58% |
| Q3 2022 | 2022-09-30 | $14.81B | $470.0M | +3.28% |
| Q2 2022 | 2022-06-30 | $14.58B | $624.0M | +4.47% |
| Q1 2022 | 2022-03-31 | $13.54B | $528.0M | +4.06% |
| Q4 2021 | 2021-12-31 | $14.89B | $1.03B | +7.42% |
| Q3 2021 | 2021-09-30 | $14.34B | $1.44B | +11.16% |
| Q2 2021 | 2021-06-30 | $13.96B | $3.53B | +33.90% |
| Q1 2021 | 2021-03-31 | $13.01B | $4.39B | +50.95% |
| Q4 2020 | 2020-12-31 | $13.86B | $5.15B | +59.21% |
| Q3 2020 | 2020-09-30 | $12.90B | $4.42B | +52.16% |
| Q2 2020 | 2020-06-30 | $10.43B | $2.17B | +26.29% |
| Q1 2020 | 2020-03-31 | $8.62B | $791.0M | +10.10% |
| Q4 2019 | 2019-12-31 | $8.70B | $399.0M | +4.80% |
| Q3 2019 | 2019-09-30 | $8.48B | $243.0M | +2.95% |
| Q2 2019 | 2019-06-30 | $8.26B | −$23.0M | −0.28% |
| Q1 2019 | 2019-03-31 | $7.83B | −$106.0M | −1.34% |
| Q4 2018 | 2018-12-31 | $8.30B | $566.0M | +7.31% |
| Q3 2018 | 2018-09-30 | $8.24B | $1.24B | +17.74% |
| Q2 2018 | 2018-06-30 | $8.28B | $1.33B | +19.21% |
| Q1 2018 | 2018-03-31 | $7.93B | $1.40B | +21.35% |
| Q4 2017 | 2017-12-31 | $7.74B | $943.0M | +13.88% |
| Q3 2017 | 2017-09-30 | $7.00B | $563.0M | +8.75% |
| Q2 2017 | 2017-06-30 | $6.94B | $492.0M | +7.63% |
| Q1 2017 | 2017-03-31 | $6.54B | $580.0M | +9.73% |
| Q4 2016 | 2016-12-31 | $6.80B | $396.0M | +6.19% |
| Q3 2016 | 2016-09-30 | $6.43B | $488.0M | +8.21% |
| Q2 2016 | 2016-06-30 | $6.45B | $977.0M | +17.84% |
| Q1 2016 | 2016-03-31 | $5.96B | $918.0M | +18.21% |
| Q4 2015 | 2015-12-31 | $6.40B | $948.0M | +17.39% |
| Q3 2015 | 2015-09-30 | $5.94B | $925.0M | +18.43% |
| Q2 2015 | 2015-06-30 | $5.47B | $549.0M | +11.14% |
| Q1 2015 | 2015-03-31 | $5.04B | $477.0M | +10.45% |
| Q4 2014 | 2014-12-31 | $5.45B | $341.0M | +6.67% |
| Q3 2014 | 2014-09-30 | $5.02B | $361.0M | +7.75% |
| Q2 2014 | 2014-06-30 | $4.93B | $234.0M | +4.99% |
| Q1 2014 | 2014-03-31 | $4.56B | $234.0M | +5.41% |
| Q4 2013 | 2013-12-31 | $5.11B | −$95.0M | −1.82% |
| Q3 2013 | 2013-09-30 | $4.66B | $150.0M | +3.33% |
| Q2 2013 | 2013-06-30 | $4.69B | $199.0M | +4.43% |
| Q1 2013 | 2013-03-31 | $4.33B | $156.0M | +3.74% |
| Q4 2012 | 2012-12-31 | $5.21B | — | — |
| Q3 2012 | 2012-09-30 | $4.51B | — | — |
| Q2 2012 | 2012-06-30 | $4.49B | — | — |
| Q1 2012 | 2012-03-31 | $4.17B | — | — |
AbbVie revenue growth trends
Over the last five reported fiscal years, revenue grew from $45.80B to $61.16B, a compound annual growth rate of 5.95%. AbbVie's latest reported quarter, Q2 2026, generated $16.99B in revenue, an increase of 10.16% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review AbbVie source filings ↗Community posts
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...
